Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
15.25
+0.35 (2.35%)
Aug 4, 2025, 4:00 PM - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 5 analysts that cover Blueprint Medicines stock have a consensus rating of "Strong Buy" and an average price target of $25.6, which forecasts a 67.87% increase in the stock price over the next year. The lowest target is $17 and the highest is $34.
Price Target: $25.60 (+67.87%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +122.95% | Jul 23, 2025 |
| Wedbush | Wedbush | Buy Initiates $17 | Buy | Initiates | $17 | +11.48% | Jul 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +24.59% | Apr 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +24.59% | Feb 25, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $28 | Buy | Initiates | $28 | +83.61% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
2.55M
from 167.50M
Decreased by -98.48%
Revenue Next Year
n/a
from 2.55M
EPS This Year
-3.73
from 1.25
EPS Next Year
-3.58
from -3.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.1M | n/a | 13.1M |
| Avg | 2.6M | n/a | 2.6M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -92.2% | - | - |
| Avg | -98.5% | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.27 | -3.01 | -2.78 |
| Avg | -3.73 | -3.58 | -3.37 |
| Low | -4.83 | -4.05 | -3.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.